Beyond Air reported $1.8 million in revenue for Q2 FY2026 with a net loss of $7.9 million, or $11.00 per share. The company reaffirmed full-year 2026 revenue guidance of $8 million and 2027 guidance of $16-$18 million. Beyond Air secured an up to $30.1 million financing, including $10.2 million in upfront proceeds and warrants tied to FDA approval for its second-generation LungFit PH system. The company regained Nasdaq compliance and entered a national GPO agreement expanding reach by nearly 2,000 hospitals. Additionally, Beyond Air announced a transition of its fiscal year-end from March 31 to December 31 effective December 31, 2026. Beyond Air is a medical device and biopharmaceutical company focused on nitric oxide therapies for respiratory illnesses.
